Johnson & Johnson Beats Wall Street Expectations; Raises Sales Forecasts
Following Latest Round of Price Hikes on Brand Name Prescription Drugs Earlier
This Month





 



BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Johnson & Johnson Beats Wall Street Expectations; Raises Sales Forecasts
Following Latest Round of Price Hikes on Brand Name Prescription Drugs Earlier
This Month



This week, Big Pharma giant Johnson & Johnson reported fourth quarter earnings,
beating
<[link removed]>
Wall Street analysts’ expectations. The expectation-beating earnings report
comes on the heels of Johnson & Johnson hiking prices on 15 prescription drugs
in its portfolio earlier this month.



During Johnson & Johnson’s fourth quarter earnings call
<[link removed]>
, Joaquin Duato, chief executive officer (CEO) of Johnson & Johnson, was
bullish on continued growth of the drug companies’ already blockbuster profits
(being fueled by egregious pricing practices and anti-competitive tactics that
keep price high for American patients): “These moves fuel our confidence that
growth in 2026 would be faster than in 2025. And we have line of sight to
double-digit growth by the end of the decade, which is notable as Johnson &
Johnson is the only healthcare company that will soon deliver more than $100
billion in annual revenue.”



Get a full recap of Johnson & Johnson’s Q4 earnings here:



Johnson & Johnson

* Johnson & Johnson reported fourth quarter earnings
<[link removed]> well
ahead of Wall Street analysts’ expectations.
* The Big Pharma giant brought in sales of $24.56 billion
<[link removed]>
, beating expectations of $24.1 billion.
* The company’s multiple myeloma treatment Darzalex, saw $3.9 billion
<[link removed]>
in Q4 sales, with total sales of$14.4 billion
<[link removed]>
for 2025.
* Johnson & Johnson forecasts sales of $99.5 billion to $100.5 billion
<[link removed]> for
2026, up from $93.5 billion to $93.9 billion in 2025.
Johnson & Johnson’s earnings go hand in hand with the steady pattern of hiking
prices on blockbuster drugs.


Johnson & Johnson

* Johnson & Johnson has hiked prices on 15 prescription drugs
<[link removed]> so far in 2026, including a
five percent increase on psoriasis drug Stelara.
* Johnson & Johnson hiked prices on 31 prescription drugs
<[link removed]> in 2025, including a 5.5
percent increase on multiple myeloma drug Darzalex and a 4.7 percent increase
on psoriasis drug Stelara.
* Johnson & Johnson engaged in 35 price hikes
<[link removed]> in 2024, including a 6.3
percent increase on Darzalex, and 5 percent increases on Erleada and Stelara.
* According to a December 2024 ICER report
<[link removed]>, price
hikes that were unsupported by new clinical evidence on the multiple myeloma
drug Darzalex led to additional consumer spending of$190 million
<[link removed]>.
* Johnson & Johnson also engaged in 36 price hikes
<[link removed]> in 2023, including a 4.5
percent increase on Darzalex, a 5 percent increase on Erleada and a 4 percent
increase on Stelara.
* Spending on the company’s blockbuster cancer drug Imbruvica is expected to
exceed $41 billion <[link removed]> between 2027 and 2036,
thanks to an anti-competitive patent scheme that extended a monopoly on the
high-priced cancer drug by more than nine years. Imbruvica costs an eye-popping
$180,000 per year
<[link removed]>
.
Stay tuned as we continue to monitor fourth quarter earnings calls from brand
name drug companies in the coming weeks.



Learn more about solutions to lower prescription drug prices and hold Big
Pharma accountableHERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>